Rheumatology, Osteoarthritis, Biomarkers
1. Jul 2021
Does moderate intensity impact exercise and non-impact exercise induce acute changes in collagen biochemical markers related to osteoarthritis? - An exploratory randomized cross-over trial
ABSTRACT
Objective: To investigate acute changes in biochemical markers of cartilage turnover in response to moderate intensity exercise with and without joint impact in humans with knee osteoarthritis.
Design: We conducted a randomized, cross-over, exploratory clinical study. Twenty subjects wi…
Read the publication
Journal:
Authors:
- Bjerre-Bastos JJ,
- Nielsen HB,
- Andersen JR,
- Karsdal MA,
- Bay-Jensen AC,
- Boesen M,
- Mackey AL,
- Byrjalsen I,
- Bihlet AR,
Rheumatology, Osteoarthritis
7. May 2021
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
ABSTRACT
Objective: The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safet…
Read the publication
Journal:
Authors:
- Eckstein F,
- Hochberg MC,
- Guehring H,
- Moreau F,
- Ona V,
- Bihlet AR,
- Byrjalsen I,
- Andersen JR,
- Daelken B,
- Guenther O,
- Ladel C,
- Michaelis M,
- Conaghan PG,
Rheumatology, Osteoarthritis
1. Apr 2021
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial
ABSTRACT
Objective: To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further progression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin.
Methods: Patients were randomised 1:1:1:1:1 to: sprifermin 100 µg every 6 months (q6mo), 100…
Read the publication
Journal:
Authors:
- Guehring H,
- Moreau F,
- Daelken B,
- Ladel C,
- Guenther O,
- Bihlet AR,
- Wirth W,
- Eckstein F,
- Hochberg M,
- Conaghan PG,
Rheumatology, Osteoarthritis, Biomarkers, Rheumatoid Arthritis
22. Mar 2021
Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis
ABSTRACT
The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have shown to be associated with disease act…
Read the publication
Journal:
Authors:
- Bay-Jensen AC,
- Bihlet AR,
- Byrjalsen I,
- Andersen JR,
- Riis BJ,
- Christiansen C,
- Michaelis M,
- Guehring H,
- Ladel C,
- Karsdal MA,